VEGFA and hepatocellular carcinoma: The first to be approved for the treatment of many solid tumors was bevacizumab, an anti-VEGF ligand antibody, which is currently being investigated for its therapeutic efficacy in HCC in several Phase III clinical trials, particularly in combination with atezolizumab (NCT04487067, NCT04732286, NCT04102098, NCT03434379, and NCT05904886).